Our data indicate that the addition of Aspirin or of Atenolol to Metformin might be beneficial for BC control , and that this activity is likely due to effects on both BC and microenvironment cells .
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models. Since metformin is frequently used along with aspirin or beta-blockers, we investigated the effect of metformin, aspirin and the beta-blocker atenolol in several BC models. In vitro, aspirin synergized with metformin in inducing apoptosis of triple negative and endocrine-sensitive BC cells, and in activating AMPK in BC and in white adipose tissue (WAT) progenitors known to cooperate to BC progression. Both aspirin and atenolol added to the inhibitory effect of metformin against complex I of the respiratory chain. In both immune-deficient and immune-competent preclinical models, atenolol increased metformin activity against angiogenesis, local and metastatic growth of HER2+ and triple negative BC. aspirin increased the activity of metformin only in immune-competent HER2+ BC models. Both aspirin and atenolol, when added to metformin, significantly reduced the endothelial cell component of tumor vessels, whereas pericytes were reduced by the addition of atenolol but not by the addition of aspirin. Our data indicate that the addition of Aspirin or of Atenolol to Metformin might be beneficial for BC control , and that this activity is likely due to effects on both BC and microenvironment cells .
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models. Since metformin is frequently used along with aspirin or beta-blockers, we investigated the effect of metformin, aspirin and the beta-blocker atenolol in several BC models. In vitro, aspirin synergized with metformin in inducing apoptosis of triple negative and endocrine-sensitive BC cells, and in activating AMPK in BC and in white adipose tissue (WAT) progenitors known to cooperate to BC progression. Both aspirin and atenolol added to the inhibitory effect of metformin against complex I of the respiratory chain. In both immune-deficient and immune-competent preclinical models, atenolol increased metformin activity against angiogenesis, local and metastatic growth of HER2+ and triple negative BC. aspirin increased the activity of metformin only in immune-competent HER2+ BC models. Both aspirin and atenolol, when added to metformin, significantly reduced the endothelial cell component of tumor vessels, whereas pericytes were reduced by the addition of atenolol but not by the addition of aspirin. Our data indicate that the addition of Aspirin or of Atenolol to Metformin might be beneficial for BC control , and that this activity is likely due to effects on both BC and microenvironment cells .

            ### Response:
            Aspirin, Atenolol, Metformin
            